Cardiff Oncology Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Cardiff Oncology stock has a consensus rating of "Buy" and an average price target of $5.36. The average 1-year stock price forecast is 354.24% higher than the current stock price, while the lowest is $2.00 (+69.49%) and the highest is $12 (+916.95%).

Price Target: $5.36 (+354.24%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$2.00	$5.36	$4.00	$12
Change	+69.49%	+354.24%	+238.98%	+916.95%

Analyst Ratings

The average analyst rating for Cardiff Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	7	6	6	6	6	3
Buy	1	1	1	1	1	1
Hold	1	1	1	1	1	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	9	8	8	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Christopher Liu Lucid Capital	Lucid Capital	Buy Maintains $10 → $4	Buy	Maintains	$10 → $4	+238.98%	Jun 5, 2026
Marc Frahm TD Cowen	TD Cowen	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Jun 4, 2026
Andy Hsieh William Blair	William Blair	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Jun 3, 2026
Albert Lowe Craig-Hallum	Craig-Hallum	Hold Downgrades $2	Hold	Downgrades	$2	+69.49%	Jun 3, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Hold Downgrades n/a	Hold	Downgrades	n/a	n/a	Jun 1, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

229.56K

from 593.00K

-61.29%

from 593.00K

Revenue Next Year

189.29K

from 229.56K

-17.54%

from 229.56K

EPS This Year

-0.69

from -0.69

EPS Next Year

-0.81

from -0.69

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	359.00K	386.00K	488.00K	683.00K	593.00K	229.56K
Revenue Growth	-1.91%	7.52%	26.42%	39.96%	-13.18%	-61.29%
Gross Profit	-17.02M	-26.72M	-32.37M	-36.17M	-34.74M	114.78K
Gross Margin	-4,740.11%	-6,922.54%	-6,632.99%	-5,295.61%	-5,857.67%	50.00%
Operating Income	-28.86M	-39.90M	-45.41M	-48.65M	-48.96M	-51.54M
Net Income	-28.29M	-38.70M	-41.44M	-45.43M	-45.85M	-50.19M
EPS	-	-	-	-	-0.69	-0.69
Free Cash Flow	-16.74M	-21.04M	-18.01M	-22.53M	-19.62M	-48.00M
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	491,000
Avg	229,560
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	-17.2%
Avg	-61.3%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-0.56
Avg	-0.69
Low	-0.78

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-